Management of mixed hyperlipidaemia

European Heart Journal

Volumn 26, Issue 9, 2005, Pages 856-857

  Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; EDITORIAL; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; PROCETOFEN;

EID: 18744404250     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi215     Document Type: Editorial

References (14)

1. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999;83:3F-12F.
2. Bredie SJ, Demacker PN, Stalenhoef AF. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest 1997;27:801-811.
3. de Graaf J, Hak-Lemmers HL, Hectors MP et al. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298-306.
4. de Graaf J, Hendriks JC, Demacker PN et al. Identification of multiple dense low-density lipoprotein subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalisation after clofibrate treatment. Arterioscler Thromb 1993;13:712-719.
5. Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidemia. Am J Cardiol 2002;90(Suppl.):21K-29K.
6. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
7. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis (Letter). N Engl J Med 2002;346:539-540.
8. Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-463.
9. Jones PH, Davidson MH. Reporting rates of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-122.
10. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J 2004;148:S9-S13.
11. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
12. Farnier M, Freeman M, Macdonnell G et al. for the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005;26:897-907. First published on March 21, 2005, doi:10.1093/eurheartj/ehi231.
13. Sudhop T, Lütjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106: 1943-1948.
14. Kosoglu T, Statkevich P, Fruchart JC et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197-1207.